- Home
- CNX vs SLNO Comparison
CNX vs SLNO Comparison
Compare CNX & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNX
- SLNO
- Stock Information
- Founded
- CNX 1860
- SLNO 1999
- Country
- CNX United States
- SLNO United States
- Employees
- CNX N/A
- SLNO N/A
- Industry
- CNX Oil & Gas Production
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CNX Energy
- SLNO Health Care
- Exchange
- CNX Nasdaq
- SLNO Nasdaq
- Market Cap
- CNX 4.5B
- SLNO 3.7B
- IPO Year
- CNX 1999
- SLNO 2014
- Fundamental
- Price
- CNX $37.03
- SLNO $47.48
- Analyst Decision
- CNX Hold
- SLNO Strong Buy
- Analyst Count
- CNX 11
- SLNO 9
- Target Price
- CNX $33.00
- SLNO $114.89
- AVG Volume (30 Days)
- CNX 2.0M
- SLNO 2.3M
- Earning Date
- CNX 10-30-2025
- SLNO 11-04-2025
- Dividend Yield
- CNX N/A
- SLNO N/A
- EPS Growth
- CNX N/A
- SLNO N/A
- EPS
- CNX 2.02
- SLNO N/A
- Revenue
- CNX $1,930,542,000.00
- SLNO $98,675,000.00
- Revenue This Year
- CNX $44.07
- SLNO N/A
- Revenue Next Year
- CNX $4.49
- SLNO $181.30
- P/E Ratio
- CNX $18.38
- SLNO N/A
- Revenue Growth
- CNX 40.99
- SLNO N/A
- 52 Week Low
- CNX $27.00
- SLNO $41.50
- 52 Week High
- CNX $41.93
- SLNO $90.32
- Technical
- Relative Strength Index (RSI)
- CNX 72.21
- SLNO 34.34
- Support Level
- CNX $31.47
- SLNO $41.80
- Resistance Level
- CNX $37.77
- SLNO $50.78
- Average True Range (ATR)
- CNX 1.04
- SLNO 3.68
- MACD
- CNX 0.41
- SLNO -2.05
- Stochastic Oscillator
- CNX 87.81
- SLNO 19.37
About CNX CNX Resources Corporation
CNX Resources Corp is an independent low carbon intensity natural gas and midstream company engaged in the exploration, development, production and acquisition of natural gas properties in the Appalachian Basin. The company's operating segment include Shale and Coalbed Methane. It generates maximum revenue from the Shale segment. It also has other segment that includes nominal shallow oil and gas production.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.